Oleg Lunov

Dr. Oleg Lunov

Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2011 in ACS Nano
Verified
Journal Article
Closed access
Oleg LunovOleg Lunov
Oleg Lunov
TSTatiana Syrovets
Tatiana Syrovets
CLCornelia Loos
Cornelia Loos
JBJohanna Beil
Johanna Beil
MDMichael Delacher
Michael Delacher
TSThomas Simmet
Thomas Simmet

15 April 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SLStefanie Lindner
Stefanie Lindner
KDKaren Dahlke
Karen Dahlke
KSKai Sontheimer
Kai Sontheimer
MHMagdalena Hagn
Magdalena Hagn
CKChristof Kaltenmeier
Christof Kaltenmeier
BJBernd Jahrsdörfer
Bernd Jahrsdörfer
The pathogenic impact of tumor-infiltrating B cells is unresolved at present, however, some studies suggest that they may have immune regulatory potential. Here, we report that the microenvironment of various solid tumors includes B cells that express granzyme B (GrB, GZMB), where these B cells can be found adjacent to interleukin (IL)-21–secreting regulatory T cells (Treg) that contribute to immune tolerance of tumor antigens. Because Tregs and plasmacytoid dendritic cells are known to modulate T-effector cells by a GrB-dependent mechanism, we hypothesized that a similar process may operate to modulate regulatory B cells (Breg). IL-21 induced outgrowth of B cells expressing high levels of GrB, which thereby limited T-cell proliferation by a GrB-dependent degradation of the T-cell receptor ζ-chain. Mechanistic investigations into how IL-21 induced GrB expression in B cells to confer Breg function revealed a CD19+CD38+CD1d+IgM+CD147+ expression signature, along with expression of additional key regulatory molecules including IL-10, CD25, and indoleamine-2,3-dioxygenase. Notably, induction of GrB by IL-21 integrated signals mediated by surface immunoglobulin M (B-cell receptor) and Toll-like receptors, each of which were enhanced with expression of the B-cell marker CD5. Our findings show for the first time that IL-21 induces GrB+ human Bregs. They also establish the existence of human B cells with a regulatory phenotype in solid tumor infiltrates, where they may contribute to the suppression of antitumor immune responses. Together, these findings may stimulate novel diagnostic and cell therapeutic approaches to better manage human cancer as well as autoimmune and graft-versus-host pathologies. Cancer Res; 73(8); 2468–79. ©2013 AACR.

23 November 2011 in ACS Nano
Verified
Journal Article
Closed access
Oleg LunovOleg Lunov
Oleg Lunov
TSTatiana Syrovets
Tatiana Syrovets
CLCornelia Loos
Cornelia Loos
GNG. Ulrich Nienhaus
G. Ulrich Nienhaus
VMVolker Mailänder
Volker Mailänder
TSThomas Simmet
Thomas Simmet

18 November 2016 in Scientific Reports
Verified
Journal Article
Open access
VZVitalii Zablotskii
Vitalii Zablotskii
TPTatyana Polyakova
Tatyana Polyakova
Oleg LunovOleg Lunov
Oleg Lunov
Alexandr DejnekaAlexandr Dejneka
Alexandr Dejneka
The biological effects of high-gradient magnetic fields (HGMFs) have steadily gained the increased attention of researchers from different disciplines, such as cell biology, cell therapy, targeted stem cell delivery and nanomedicine. We present a theoretical framework towards a fundamental understanding of the effects of HGMFs on intracellular processes, highlighting new directions for the study of living cell machinery: changing the probability of ion-channel on/off switching events by membrane magneto-mechanical stress, suppression of cell growth by magnetic pressure, magnetically induced cell division and cell reprograming, and forced migration of membrane receptor proteins. By deriving a generalized form for the Nernst equation, we find that a relatively small magnetic field (approximately 1 T) with a large gradient (up to 1 GT/m) can significantly change the membrane potential of the cell and thus have a significant impact on not only the properties and biological functionality of cells but also cell fate.

4 May 2012 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
TSTatiana Syrovets
Tatiana Syrovets
Oleg LunovOleg Lunov
Oleg Lunov
TSThomas Simmet
Thomas Simmet
Review of the available evidence for physiological and pathophysiological roles of the serine protease plasmin in inflammatory processes. The serine protease plasmin generated from its zymogen plasminogen is best known for its function as a key enzyme of the fibrinolytic cascade. However, beyond fibrinolysis, plasmin has a number of crucial functions in a variety of processes, including inflammation. Various cells can bind plasminogen and plasmin via plasminogen-binding sites exposing a C-terminal lysine. Plasmin, generated as a result of plasminogen activation at the cell surface, is protected from its physiological inhibitors. Apart from its ability to facilitate cell migration in tissues, plasmin is capable of triggering signaling, which depends on cellular binding via its lysine-binding sites and its proteolytic activity. Plasmin-induced signaling affects various functions of monocytes, macrophages, DCs, and others, with the list of affected cells still growing. In vitro and in vivo studies have demonstrated the ability of plasmin to stimulate the production of cytokines, ROS, and other mediators, thereby contributing to inflammation. Plasmin-induced chemotaxis of monocytes and DCs indicates that it is also a potent chemoattractant for immune cells. Therefore, excessive activation of plasmin in chronic inflammatory or autoimmune diseases might exacerbate the activation of inflammatory cells and the pathogenesis of the disease. This review focuses on the available evidence for physiological and pathophysiological roles the serine protease plasmin in inflammatory processes.

11 February 2010 in Blood
Verified
Journal Article
Open access
PDF file
BJBernd Jahrsdörfer
Bernd Jahrsdörfer
AVAngelika Vollmer
Angelika Vollmer
SBSue E. Blackwell
Sue E. Blackwell
JMJulia Maier
Julia Maier
KSKai Sontheimer
Kai Sontheimer
DFDorit Fabricius
Dorit Fabricius
Human plasmacytoid dendritic cells (pDCs) are crucially involved in the modulation of adaptive T-cell responses in the course of neoplastic, viral, and autoimmune disorders. In several of these diseases elevated extracellular levels of the serine protease granzyme B (GrB) are observed. Here we demonstrate that human pDCs can be an abundant source of GrB and that such GrB+ pDCs potently suppress T-cell proliferation in a GrB-dependent, perforin-independent manner, a process reminiscent of regulatory T cells. Moreover, we show that GrB expression is strictly regulated on a transcriptional level involving Janus kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), and STAT5 and that interleukin-3 (IL-3), a cytokine secreted by activated T cells, plays a central role for GrB induction. Moreover, we find that the immunosuppressive cytokine IL-10 enhances, while Toll-like receptor agonists and CD40 ligand strongly inhibit, GrB secretion by pDCs. GrB-secreting pDCs may play a regulatory role for immune evasion of tumors, antiviral immune responses, and autoimmune processes. Our results provide novel information about the complex network of pDC–T-cell interactions and may contribute to an improvement of prophylactic and therapeutic vaccinations.